In Europe, the technology has been protected since March 2018 - now this protection has been expanded for the US. "The US are an important market for our technology and we are now focusing on further validating our solution and bringing it to market," says Norman Gerstner, Project Manager at ProDetekt.

ELISA (Enzyme-linked Immunosorbent Assay) is a standard test for disease-relevant biomarkers. PRET ELISA is an extension of the method used worldwide in bioanalytics. The new method is based on the use of an enzyme cascade and the cleavage of a peptide substrate, which enhances the fluorescence signal. With the help of this method, significant increases in performance and efficiency can be achieved and the standard ELISA tests can still be used. The newly developed technologies enable the exact detection of even low concentrations of biomarkers and thus a more targeted diagnosis. In many diseases, the corresponding biomarkers can even be detected before the onset of the first typical symptoms; early diagnosis and therapy always improves the prognosis for the patient.

In the Life Science Incubator in Saxony, innovative projects in biotechnology, the life sciences and medical technology are being evaluated at an early stage and developed with the project group up to financing and market maturity. The Pro-Detekt project was funded by the German Federal Ministry of Education and Research (BMBF) until June 2018 as part of the LSI.

Read more about the Life Science Incubator here.